Study of TB Infection Risk and Immune Response in Health Workers in Cape Town
Using New and Established Tests Over One Year
Led by Beth Israel Deaconess Medical Center · Updated on 2026-07-08
300
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Tuberculosis TB is a major infectious disease affecting many people worldwide, including health workers in Cape Town, South Africa, who face a high risk of TB infection. This research is a prospective longitudinal study aiming to better understand TB infection by evaluating immune and pathogen responses over time in health workers using a combination of new and established tests. The study focuses on identifying which people exposed to TB may remain at risk for developing active TB disease, through detailed monitoring of their immune responses and infection markers.
Participants in this study will undergo serial testing every 3 months for one year and again at 24 months using established and novel diagnostic tools. These tests include interferon gamma release assays IGRAs, blood RNA biosignatures, TB-specific antibody responses, and assays to detect TB DNA. The study will track changes in these markers over time to learn more about early infection, immune response dynamics, and potential infection clearance or persistence.
During the study, health workers will be tested at months 0, 3, 6, 9, 12, and 24 to monitor TB infection status and detect any development of TB disease. Researchers will collect blood samples and perform various laboratory tests to measure immune markers and pathogen presence. The main outcome measured is IGRA conversion indicating new TB infection. Safety and health status will be monitored throughout participation, which may last over two years, to better understand TB infection progression in a population at high risk.
CONDITIONS
Brief Title
Testing Health Workers At Risk to Advance Our Understanding of TB Infection
Research Team
R
Ruvandhi Nathavitharana, MBBS MPH
G
Grant Theron, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Prior history of tuberculosis or positive interferon gamma release assay (IGRA)
Current or past use of anti-tuberculosis treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - 2 years
Participants undergo regular testing every 3 months for one year and again at 24 months using established and novel assays to evaluate immune responses and detect TB infection or disease.
Testing at months 0, 3, 6, 9, 12, and 24
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Testing a 1-Month Ultra-Short Treatment to Prevent Active Tuberculosis in School Contacts
Comparing 1H3P3 and 3HR Regimens in Adolescents and School Staff
Phase 2b Study Comparing JDB0131 Benzenesulfonate Tablets and Delamanid
in Combination Treatments for Rifampin-Resistant Tuberculosis
Safety and Drug Level Study of Isoniazid Inhalation by Wet Nebulization in Adults with Tuberculosis
Dose Finding and Safety Study of Daily Rifapentine with Isoniazid for Tuberculosis Prevention in Children Under 13 With and Without HIV
Phase 2 Open-label Study of Oral Alpibectir with Ethionamide and with Rifampicin, Pyrazinamide, and Ethambutol in Adults with Newly Diagnosed Drug-Susceptible Pulmonary Tuberculosis
Phase 1 Study of Oral Microgynon and Ganfeborole Interaction in Healthy Non-Childbearing Female Adults Aged 18 to 64 Years
Screening for Tuberculosis in High-Risk Groups Living in Barcelona
Study on Screening for Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
Comparing Moderate Drinking Advice to Abstention Advice for Adults 50 to 75 Years to Prevent Major Diseases and Death
Supporting and Accelerating Tuberculosis Research Through Assessment of New Point-of-Care Diagnostic Tests
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Predicting Airborne Infection Risk: Association Between Personal Ambient Carbon Dioxide Level Monitoring and Incidence of Tuberculosis Infection in South African Health Workers.
Ruvandhi R Nathavitharana, Hridesh Mishra, Amanda Sullivan...